AcTFirst: A phase III, open-label, multi-center, randomized study comparing AAA817+ARPI versus standard of care in adult participants with PSMA-positive metastatic castration-resistant prostate cancer
Sponsor: Novartis Pharma AG
Phase: 3
Disease: Metastatic castration-resistant prostate cancer, PSMA-positive metastatic castration-resistant prostate cancer
EU trial number: 2024-512340-32-01
Population: Adults ≥18 years with histologically/cytologically confirmed prostate adenocarcinoma, PSMA-PET-positive metastatic castration-resistant disease progressing on their last androgen receptor pathway inhibitor (ARPI), ECOG performance status 0–2, maintaining castration; prior taxane chemotherapy in mCRPC is excluded.
Register Investigator Interest
Interested in offering this trial to suitable patients?